LNCaP cell line was obtained from ATCC, the v-Src PEC and the NeuT-PEC cell lines were previously described (18 (link)). Original cells were expanded and stored in the liquid nitrogen at early passage. During the experiments, the morphology of all cell lines was checked under phase contrast microscope routinely. For LNCaP cell line, proliferation and AR abundance in response to DHT stimulation were tested by MTT assay and Western-blot. For v-Src-PEC and NeuT-PEC cell lines, the proliferation in response to Src kinase inhibitor or NeuT inhibitor was tested. V-Src or NeuT expression in these cells was checked by Western-blot for verification. All of the newly revived cells were treated with BM-cyclins (Roche) and the mycoplasma contamination was determined with Hoechst 33258 staining under high magnification fluorescent microscope routinely. DNA transfection and luciferase assays were performed as previously described (1 (link),18 (link)). The CBF-Luc and -3,400 cyclin D1-Luc reporter plasmids were previously described (19 (link),20 (link)). The Src kinase inhibitor PP1 (4-amino-5-(4-methylphenyl)-7-(t-butel)pyrazolo-d-3-4-pyrimidine (Calbio Chem) and Dasatinib (BMS-354825, Selleckchem), the CDK inhibitor Abemaciclib (MedChem Express), Palbociclib (Sigma-Aldrich), Ribociclib (Selleckchem) and the EGFR inhibitor Canertinib (Selleckchem) were used at the indicated doses.